NCT05717348View on ClinicalTrials.gov

A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

February 24, 2023

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions

Solid TumorLocally Advanced Solid TumorMetastatic Solid Tumor

Interventions

DRUG

ES014

ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.

Trial Locations (1)

Unknown

Shanghai Chest Hospital, Shanghai

All Listed Sponsors

lead

Elpiscience (Suzhou) Biopharma, Ltd.

INDUSTRY